




that is an aqueous solution as the Zn2+ cations and bis(glycerol)borate anions 
[B(C3H6O3)2]
‒ . 
The simultaneous presence of these ions, in our opinion, provides the increased 
antimicrobial activity of Si-Zn-B–gel in comparison with silicon–boron- [1, 2] and 
silicon–zinc-glycerol [1,3] hydrogels. Thus, Si-Zn-B–gel can be an efficient and safer 
alternative to conventional topical antimicrobial agents for treatment of diseases of skin 
and mucous membrane. 
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In 2015, there were an estimated 415 million people diagnosed with DM in the 





complications (cardiovascular disease, retinopathy, renal failure, encephalopathy, 
impaired peripheral blood circulation, and others). Accumulation of advanced 
glycation end products (AGEs) in tissues is considered as a main driver of these 
complications. Non-enzymatic glycation of proteins (Maillard reaction) is the way of 
AGEs formation. 
 
We have proposed a synthetic scheme towards promising class of azoloazine 
heterocycles (1) and proved antidiabetic potential of these compounds by 
computational methods and experiments in vitro. 
 
It was shown that azoloazines (1) demonstrated higher antiglycation activity than 
reference compound, aminoguanidine, and have some potential as dipeptidylpeptidase-
4 inhibitors. By given results this class of heterocycles can be considered as candidate 
for extended studies to develop drugs against complications of T2DM [1-4]. 
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